Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
---|
11/23/2006 | WO2006124626A2 Inhibition of the 44 kilodalton isoform of pim-1 kinase restores apoptosis induced by chemotherapeutic drugs in cancer cells |
11/23/2006 | WO2006124375A2 Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders |
11/23/2006 | WO2006123827A1 Method for amelioration of disease condition induced by mood disorder |
11/23/2006 | WO2006123817A1 Method for delivering nucleic acid and device for delivering nucleic acid |
11/23/2006 | WO2006123644A1 Int6 PROTEIN INVOLVED IN HYPOXIA STRESS INDUCTION AND USE THEREOF |
11/23/2006 | WO2006123631A1 Rna-containing composition |
11/23/2006 | WO2006123248A2 Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject |
11/23/2006 | WO2006122971A2 Treatment of disease using an improved regulated expression system |
11/23/2006 | WO2006096441A3 Reagents, methods and systems to suppress phospholamban expression |
11/23/2006 | WO2006078640A3 Alterations utilizing nanoparticles |
11/23/2006 | WO2006063067A3 Novel tnf receptor regulatory domain |
11/23/2006 | WO2006060051A3 Enzyme chimeras and methods of their use for the treatment of infection by bacillus anthracis |
11/23/2006 | WO2006047250A3 Use of apoptosis inhibiting compounds in degenerative neurological disorders |
11/23/2006 | WO2006036465A3 Compositions and methods for treating cystic fibrosis |
11/23/2006 | WO2006024880A3 Methods and compositions to inhibit p2x7 receptor expression |
11/23/2006 | WO2006016097A3 Vector comprising polymer modified sirna liposomes |
11/23/2006 | WO2005118825A3 Chimeric adenoviruses for use in cancer treatment |
11/23/2006 | WO2005074995A3 Combined use of prame inhibitors and hdac inhibitors |
11/23/2006 | US20060265773 Methods for producing transgenic animals with modified disease resistance |
11/23/2006 | US20060265765 Oncogene HOXB13 and its siRNAs |
11/23/2006 | US20060265763 Dyrks as modifiersof the apc and axin pathways and methods of use |
11/23/2006 | US20060264615 Which induce proliferation of lymphocytes in presence of wild-type p35 polypeptide subunit of human interleukin-12; site directed mutagenesis |
11/23/2006 | US20060264609 Use of heat shock proteins |
11/23/2006 | US20060264396 Nucleic acid inducing RNA interference against syndecan gene expression; adminstering in vitro to inhibit cell growth |
11/23/2006 | US20060264395 Modulation of apolipoprotein c-III expression |
11/23/2006 | US20060264394 Livin-specific sirnas for the treatment of therapy-resistant tumors |
11/23/2006 | US20060264393 Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases |
11/23/2006 | US20060264392 Modulators of angiogenesis |
11/23/2006 | US20060264391 Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
11/23/2006 | US20060264371 Treatment |
11/23/2006 | US20060264366 Identifying an agent that inhibits binding of mammalian Mcl-1 with a human or mouse Mule polypeptide having a Mule BH3 domain by contacting the mixture with a candidate agent and detecting an agent-biased binding that is different from the reference binding, indicating that the agent is an inhibitor |
11/23/2006 | US20060264363 Inhibition of nerve cell death by inhibiting degradation of shc3, atf6 or crebl1 by htra2 and method of ameliorating neurodegenerative diseases |
11/23/2006 | US20060264359 inducing eosinophil apoptosis; Pin1 inhibitor is juglone |
11/23/2006 | US20060264357 Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals |
11/23/2006 | US20060263883 Recombinant herpes viruses for preparing recombinant adeno-associated viruses |
11/23/2006 | US20060263882 Multi-cistronic vectors for gene transfer protocols |
11/23/2006 | US20060263852 Asp2 |
11/23/2006 | US20060263828 Arrestin chimera comprising naturally occurring beta-arrestin-2 and naturally occurring ubiquitin moiety, where arrestin chimera has increased affinity for GPCR, and where increased affinity means that arrestin chimera remains associated with and traffics with GPCR into endosomes |
11/23/2006 | US20060263776 Serine protease |
11/23/2006 | US20060263435 nucleic acid such as siRNAs; carrier includes a cyclodextrin polymer; treatment of cell proliferative disorders, such as cancer or pathogen infections |
11/23/2006 | US20060263422 Pharmaceutical composition containing decoy and use of the same |
11/23/2006 | US20060263389 Methods and compositions to enhance immune responses via recall antigens |
11/23/2006 | US20060263381 Peptide epitopes common to antigens of the same multigene family |
11/23/2006 | US20060263359 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4) |
11/23/2006 | US20060263345 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
11/23/2006 | US20060263343 Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease |
11/23/2006 | US20060263342 Peptides derived from a protein encoded by a polynucleotide overexpressed in human colon cancer cells; bladder, prostate and breast cancers; antimetastasis agents; diagnosis |
11/23/2006 | US20060263334 Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen |
11/23/2006 | US20060263333 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection |
11/23/2006 | DE102005023993A1 Nicht virales Vektorsystem zum Transport von Nukleinsäure in die Lunge Non-viral vector system for transporting nucleic acid into the lungs |
11/23/2006 | DE102005023170A1 Optimierte Formulierung für mRNA Optimized formulation for mRNA |
11/23/2006 | DE102004054731A1 New pharmaceutical composition comprising an oligonucleotide that is adapted to target nucleic acids encoding CD40, useful for preventing or treating an inflammatory, immune or autoimmune disorder |
11/23/2006 | CA2614608A1 Anti-tumoral compositions and methods |
11/23/2006 | CA2612538A1 A method for the treatment of pompe disease using 1-deoxynojirimycin derivatives |
11/23/2006 | CA2609814A1 Method for amelioration of disease condition induced by mood disorder |
11/23/2006 | CA2609102A1 Int6 protein involved in hypoxia stress induction and use thereof |
11/23/2006 | CA2608764A1 Treatment of disease using an improved regulated expression system |
11/23/2006 | CA2607291A1 Compositions and methods for modulating immune responses |
11/23/2006 | CA2604452A1 Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject |
11/23/2006 | CA2597511A1 Hivcon: an hiv immunogen and uses thereof |
11/22/2006 | EP1724354A2 Circular DNA molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy |
11/22/2006 | EP1724353A2 Methods of forming protein-linked lipidic microparticles |
11/22/2006 | EP1724351A2 Human Kallikrein-like genes |
11/22/2006 | EP1724350A1 Method and compositions for the diagnosis and treatment of cancer |
11/22/2006 | EP1724339A1 Gene regulation therapy involving ferritin |
11/22/2006 | EP1723970A1 Medicinal composition containing cxcr3 inhibitor |
11/22/2006 | EP1723950A2 Method of treating dopaminergic gaba-nergic disorders |
11/22/2006 | EP1723417A1 C20orf23 as modifier of the igfr pathway and methods of use |
11/22/2006 | EP1723415A1 Pdes as modifiers of the igfr pathway and methods of use |
11/22/2006 | EP1723238A1 Modified oncolytic viruses |
11/22/2006 | EP1723177A2 Rab9a, rab11a, and modulators thereof related to infectious disease |
11/22/2006 | EP1723166A2 Materials and methods relating to the treatment of glioblastomas |
11/22/2006 | EP1723162A2 Anti-microrna oligonucleotide molecules |
11/22/2006 | EP1722823A2 Pharmaceutical composition |
11/22/2006 | EP1722760A2 Delivery of genes encoding short hairpin rna using receptor-specific nanocontainers |
11/22/2006 | EP1244651B1 Diamidine compounds as dna minor groove binders |
11/22/2006 | EP1214098B1 Capsid-modified recombinant adenovirus and methods of use |
11/22/2006 | EP1163522B1 Method for detecting msrv-1 induced superantigen activity in a biological sample |
11/22/2006 | EP1071774B1 Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof |
11/22/2006 | EP1053309B1 Compositions and methods for wound healing |
11/22/2006 | EP1000158B1 Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders |
11/22/2006 | EP0939821B1 G-beta-gamma regulated phosphatidylinositol-3' kinase |
11/22/2006 | EP0935415B1 In vitro methods for delivering nucleic acids into a cell |
11/22/2006 | EP0825996B1 Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use |
11/22/2006 | CN1867362A Cancer gene therapeutic drug |
11/22/2006 | CN1867361A Cancer gene therapeutic drug |
11/22/2006 | CN1865449A 病毒株 Strains |
11/22/2006 | CN1865442A SiRNA sequence aimed at hepatitis B virus gene and its uses |
11/22/2006 | CN1865284A Receptor of the edb-fibronectin domains |
11/21/2006 | US7138569 Nucleic acids encoding pseudomonas hop proteins and use thereof |
11/21/2006 | US7138517 Sugar modified oligonucleotides |
11/21/2006 | US7138512 Gene SHINC-2 and diagnostic and therapeutic uses thereof |
11/21/2006 | US7138511 Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders |
11/21/2006 | US7138508 Inhibitor protein of the wnt signal pathway |
11/21/2006 | US7138492 Promoting survival of substantia nigra neuronal cells by contacting with a trophic amount of a ptc therapeutic; mimics hedgehog-mediated patched signal transduction; treating or preventing Parkinson's Disease |
11/21/2006 | US7138383 That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity |
11/21/2006 | US7138382 Compositions and methods for drug delivery using pH sensitive molecules |
11/21/2006 | US7138381 Compositions containing nucleic acids and ligands for therapeutic treatment |
11/21/2006 | US7138380 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease |
11/21/2006 | US7138379 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons |